Chemistry:BK-6-MAPB

From HandWiki

βk-6-MAPB, or BK-6-MAPB, also known as NM-PrBF6 or as 6-[2-(methylamino)propanoyl]benzofuran, is a putative entactogen of the benzofuran and cathinone groups.[1][2] It was patented by Matthew Baggott and Tactogen.[1][3][4] The drug is known to act as a potent serotonin releasing agent.[1][5] In addition, unlike MDMA, it is a potent serotonin 5-HT1B receptor agonist.[5] βk-6-MAPB was encountered as a novel designer drug online in 2019.[2]

See also

References

  1. 1.0 1.1 1.2 Baggott M, "Advantageous benzofuran compositions for mental disorders or enhancement", WO patent 2021/252538, published 16 December 2021
  2. 2.0 2.1 "bk-MAPB". AIPSIN Monitoring. 25 June 2019. https://aipsin.com/archive_newsubstance/3/7/pdf/. 
  3. Baggott MJ, Lofthus SJ, De Leona XM, Singh A, Hudgins CJ, "Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement", WO patent 2023/107653, published 21 September 2023
  4. Baggott M, Dalziel S, "Specialized combinations for mental disorders or mental enhancement", WO patent 2023/107715, published 15 June 2023
  5. 5.0 5.1 Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", US patent 20230150963, published 2023 May 18, assigned to Tactogen